According to the literature, about 50% of COVID-19 patients were reported with GI symptoms. These patients had a higher risk to become severe cases. This implies the existence of “gut-lung axis”, and the potentiality of decreasing respiratory tract infections through microbiota composition. Based on the previous analysis experience,GenoRx devoted to developing gut-lung axis related microbiota detection kit. Help people using scientific ways to fight with the unknown disease in the future.